| Part B: Supplementary Information Sheet (SIS) |
|
FR Recognition List Number
|
030
|
Date of Entry 01/15/2013
|
|
FR Recognition Number
|
7-237
|
| Standard | |
CLSI MM01-A3 (Replaces MM01-A2) Molecular Methods for Clinical Genetics and Oncology Testing; Approved Guideline - Third Edition |
|
Scope/Abstract| This document provides general recommendations for all phases of the operation of a molecular genetics diagnostic laboratory. Clinical molecular testing has application to inherited and acquired medical conditions with genetic etiologies as well as variations associated with drug metabolism. In a clinical molecular laboratory, techniques and practices require strict adherence to quality performance measures. This revised guideline will address the total testing process. |
|
| Extent of Recognition
|
Public Law, CFR Citation(s) and Procode(s)*
| Regulation Number |
Device Name |
Device Class |
Product Code |
| §862.3360 |
Drug Metabolizing Enzyme Genotyping Systems
|
Class 2
|
NTI
|
| §864.7280 |
Test, Factor V Leiden Mutations, Genomic Dna Pcr
|
Class 2
|
NPQ
|
| §866.3170 |
Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus
|
Class 2
|
MZP
|
|
Relevant FDA Guidance and/or Supportive Publications*
| Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices - Guidance for Industry and Food and Drug Administration Staff, issued September 2018. |
|
| FDA Technical Contacts
|
| Standards Development Organization
|
| FDA Specialty Task Group (STG)
|
| *These are provided as examples and others may be applicable. |